PL4346839T3 - Kompozycje farmaceutyczne do żywienia klinicznego - Google Patents
Kompozycje farmaceutyczne do żywienia klinicznegoInfo
- Publication number
- PL4346839T3 PL4346839T3 PL22732755.8T PL22732755T PL4346839T3 PL 4346839 T3 PL4346839 T3 PL 4346839T3 PL 22732755 T PL22732755 T PL 22732755T PL 4346839 T3 PL4346839 T3 PL 4346839T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical compositions
- clinical nutrition
- nutrition
- clinical
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/332,499 US20220395516A1 (en) | 2021-05-27 | 2021-05-27 | Pharmaceutical compositions for clinical nutrition |
| PCT/US2022/030674 WO2022251177A2 (en) | 2021-05-27 | 2022-05-24 | Pharmaceutical compositions for clinical nutrition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4346839T3 true PL4346839T3 (pl) | 2025-06-09 |
Family
ID=82156761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22732755.8T PL4346839T3 (pl) | 2021-05-27 | 2022-05-24 | Kompozycje farmaceutyczne do żywienia klinicznego |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220395516A1 (pl) |
| EP (2) | EP4527844A3 (pl) |
| KR (1) | KR20240013185A (pl) |
| CN (1) | CN117396210A (pl) |
| AU (1) | AU2022281320A1 (pl) |
| CA (1) | CA3221388A1 (pl) |
| DK (1) | DK4346839T3 (pl) |
| ES (1) | ES3028084T3 (pl) |
| FI (1) | FI4346839T3 (pl) |
| HR (1) | HRP20250685T1 (pl) |
| HU (1) | HUE071938T2 (pl) |
| LT (1) | LT4346839T (pl) |
| MX (1) | MX2023014023A (pl) |
| PL (1) | PL4346839T3 (pl) |
| PT (1) | PT4346839T (pl) |
| RS (1) | RS66807B1 (pl) |
| SI (1) | SI4346839T1 (pl) |
| SM (1) | SMT202500235T1 (pl) |
| WO (1) | WO2022251177A2 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220395516A1 (en) | 2021-05-27 | 2022-12-15 | Baxter International Inc. | Pharmaceutical compositions for clinical nutrition |
| US20240335469A1 (en) * | 2023-04-04 | 2024-10-10 | Amneal Eu, Limited | Ready-to-use pharmaceutical compositions of potassium phosphates injection |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5916818A (ja) | 1982-07-20 | 1984-01-28 | Shimizu Seiyaku Kk | 経静脈投与用輸液剤 |
| RU1667364C (ru) * | 1990-01-04 | 1995-03-10 | Санкт-Петербургский химико-фармацевтический институт | Способ получения водного раствора глицерофосфата натрия |
| RO114618B1 (ro) * | 1997-09-01 | 1999-06-30 | Marin Marinescu | Procedeu de preparare a glicerofosfatului de sodiu |
| CN1517093A (zh) * | 2003-01-15 | 2004-08-04 | 华瑞制药有限公司 | 注射用甘油磷酸纳注射液与其制造方法及其应用方法 |
| CN101575348A (zh) | 2008-05-08 | 2009-11-11 | 上海中药创新研究中心 | 一种β-甘油磷酸钠的合成方法 |
| US8420848B2 (en) | 2009-01-09 | 2013-04-16 | Sigma-Aldrich Co. Llc | Process for the synthesis of beta glycerol phosphate |
| CN101851252B (zh) | 2009-09-01 | 2012-10-10 | 紫光古汉集团衡阳制药有限公司 | 甘油磷酸钠的制备方法 |
| CN104163827A (zh) | 2014-05-21 | 2014-11-26 | 江苏德峰药业有限公司 | 一种β-磷酸甘油钠的合成方法 |
| CN105732700B (zh) * | 2016-03-23 | 2018-01-16 | 江苏诚信药业有限公司 | 一种制备β‑甘油磷酸钠的方法 |
| CN111961077B (zh) * | 2020-09-11 | 2023-06-20 | 山西千岫制药有限公司 | 一种含结晶水β甘油磷酸钠的制备方法 |
| US20220395516A1 (en) | 2021-05-27 | 2022-12-15 | Baxter International Inc. | Pharmaceutical compositions for clinical nutrition |
-
2021
- 2021-05-27 US US17/332,499 patent/US20220395516A1/en active Pending
-
2022
- 2022-05-24 FI FIEP22732755.8T patent/FI4346839T3/fi active
- 2022-05-24 EP EP24210283.8A patent/EP4527844A3/en active Pending
- 2022-05-24 HU HUE22732755A patent/HUE071938T2/hu unknown
- 2022-05-24 RS RS20250488A patent/RS66807B1/sr unknown
- 2022-05-24 SI SI202230112T patent/SI4346839T1/sl unknown
- 2022-05-24 PL PL22732755.8T patent/PL4346839T3/pl unknown
- 2022-05-24 KR KR1020237044472A patent/KR20240013185A/ko active Pending
- 2022-05-24 PT PT227327558T patent/PT4346839T/pt unknown
- 2022-05-24 DK DK22732755.8T patent/DK4346839T3/da active
- 2022-05-24 LT LTEPPCT/US2022/030674T patent/LT4346839T/lt unknown
- 2022-05-24 AU AU2022281320A patent/AU2022281320A1/en active Pending
- 2022-05-24 CA CA3221388A patent/CA3221388A1/en active Pending
- 2022-05-24 HR HRP20250685TT patent/HRP20250685T1/hr unknown
- 2022-05-24 SM SM20250235T patent/SMT202500235T1/it unknown
- 2022-05-24 CN CN202280036603.XA patent/CN117396210A/zh active Pending
- 2022-05-24 MX MX2023014023A patent/MX2023014023A/es unknown
- 2022-05-24 ES ES22732755T patent/ES3028084T3/es active Active
- 2022-05-24 EP EP22732755.8A patent/EP4346839B1/en active Active
- 2022-05-24 WO PCT/US2022/030674 patent/WO2022251177A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022251177A2 (en) | 2022-12-01 |
| CA3221388A1 (en) | 2022-12-01 |
| SMT202500235T1 (it) | 2025-07-22 |
| MX2023014023A (es) | 2023-12-12 |
| EP4527844A2 (en) | 2025-03-26 |
| EP4527844A3 (en) | 2025-05-28 |
| AU2022281320A1 (en) | 2023-11-23 |
| PT4346839T (pt) | 2025-05-20 |
| FI4346839T3 (fi) | 2025-04-30 |
| US20220395516A1 (en) | 2022-12-15 |
| RS66807B1 (sr) | 2025-06-30 |
| HUE071938T2 (hu) | 2025-10-28 |
| WO2022251177A3 (en) | 2023-01-05 |
| KR20240013185A (ko) | 2024-01-30 |
| EP4346839B1 (en) | 2025-03-26 |
| ES3028084T3 (en) | 2025-06-18 |
| LT4346839T (lt) | 2025-05-12 |
| CN117396210A (zh) | 2024-01-12 |
| EP4346839A2 (en) | 2024-04-10 |
| DK4346839T3 (en) | 2025-04-14 |
| SI4346839T1 (sl) | 2025-07-31 |
| HRP20250685T1 (hr) | 2025-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202019241D0 (en) | Pharmaceutical composition | |
| IL304290A (en) | composition of drugs | |
| IL300090A (en) | Pharmaceutical preparations containing VENGLUSTAT | |
| DK4346839T3 (en) | Pharmaceutical compositions for clinical nutrition | |
| GB202010230D0 (en) | Pharmaceutical formulation | |
| GB202100526D0 (en) | Pharmaceutical formulation | |
| IL314046A (en) | RIBOCICLIB medicinal preparations | |
| GB202019335D0 (en) | Pharmaceutical compositions | |
| IL297081A (en) | Pharmaceutical formulation | |
| IL297080A (en) | Pharmaceutical formulation | |
| GB202104224D0 (en) | Pharmaceutical composition | |
| GB202018068D0 (en) | Pharmaceutical composition | |
| IL312071A (en) | medicinal preparations | |
| GB202013701D0 (en) | Pharmaceutical compositions | |
| IL324773A (en) | Pharmaceutical preparations | |
| IL320961A (en) | Milvaxian medicinal compounds | |
| GB202313738D0 (en) | Pharmaceutical compositions | |
| GB202312055D0 (en) | Pharmaceutical compositions | |
| GB202208464D0 (en) | Pharmaceutical composition | |
| GB202005742D0 (en) | Novel pharmaceutical compositions | |
| GB202109271D0 (en) | Pharmaceutical composition | |
| GB202108387D0 (en) | Pharmaceutical composition | |
| GB202107518D0 (en) | Pharmaceutical composition | |
| GB202105858D0 (en) | Pharmaceutical composition | |
| GB202105462D0 (en) | Pharmaceutical composition |